Acceleron Pharma PE Ratio 2012-2021 | XLRN

Current and historical p/e ratio for Acceleron Pharma (XLRN) from 2012 to 2021. The price to earnings ratio is calculated by taking the latest closing price and dividing it by the most recent earnings per share (EPS) number. The PE ratio is a simple way to assess whether a stock is over or under valued and is the most widely used valuation measure. Acceleron Pharma PE ratio as of October 15, 2021 is 0.00.

Please refer to the Stock Price Adjustment Guide for more information on our historical prices.

Acceleron Pharma PE Ratio Historical Data
Date Stock Price TTM Net EPS PE Ratio
2021-10-15 172.94 0.00
2021-06-30 125.49 $-3.71 0.00
2021-03-31 135.61 $-3.00 0.00
2020-12-31 127.94 $-2.90 0.00
2020-09-30 112.53 $-2.39 0.00
2020-06-30 95.27 $-2.59 0.00
2020-03-31 89.87 $-2.59 0.00
2019-12-31 53.02 $-2.38 0.00
2019-09-30 39.51 $-2.69 0.00
2019-06-30 41.08 $-2.46 0.00
2019-03-31 46.57 $-2.75 0.00
2018-12-31 43.55 $-2.59 0.00
2018-09-30 57.23 $-2.46 0.00
2018-06-30 48.52 $-2.48 0.00
2018-03-31 39.10 $-2.62 0.00
2017-12-31 42.44 $-2.70 0.00
2017-09-30 37.32 $-2.59 0.00
2017-06-30 30.39 $-2.49 0.00
2017-03-31 26.47 $-2.31 0.00
2016-12-31 25.52 $-1.52 0.00
2016-09-30 36.19 $-1.82 0.00
2016-06-30 33.98 $-1.63 0.00
2016-03-31 26.39 $-1.36 0.00
2015-12-31 48.76 $-1.94 0.00
2015-09-30 24.90 $-1.68 0.00
2015-06-30 31.64 $-1.57 0.00
2015-03-31 38.06 $-1.77 0.00
2014-12-31 38.96 $-1.62 0.00
2014-09-30 30.24 $-1.71 0.00
2014-06-30 33.97 $-7.08 0.00
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $10.532B $0.093B
Acceleron Pharma Inc. is a biopharmaceutical company which focuses on the discovery, development and commercialization of protein therapeutics for cancer and rare diseases. Acceleron Pharma Inc. is based in Cambridge, Massachusetts.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $129.683B 8.63
Bio-Rad Laboratories (BIO.B) United States $21.975B 46.83
QIAGEN (QGEN) Netherlands $11.773B 19.94
Biohaven Pharmaceutical Holding (BHVN) United States $8.738B 0.00
Emergent Biosolutions (EBS) United States $2.722B 6.57
Arcus Biosciences (RCUS) United States $2.455B 0.00
Myovant Sciences (MYOV) United Kingdom $1.915B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.755B 0.00
Zymeworks (ZYME) Canada $1.208B 0.00
Ambrx Biopharma (AMAM) United States $0.470B 0.00
SQZ Biotechnologies (SQZ) United States $0.342B 0.00
Enzo Biochem (ENZ) United States $0.183B 18.00